Neutrophil-to-Lymphocyte Ratio, Platelet-to-Lymphocyte Ratio, and Their Variations as a Basis for a Prediction Model in Advanced NSCLC Patients Receiving Anlotinib

Table 1

Patients’ basic characteristics.

Characteristics	Patients (%)
Age (years)
Median	63 years
Range	32-84
<65	91 (59.9%)
≥65	61 (40.1%)
Gender
Male	110 (72.4%)
Female	42 (27.6%)
Performance status (ECOG)
0-1	110 (72.4%)
2-3	42 (27.6%)
Pathology
Adenocarcinoma	69 (45.4%)
Squamous carcinoma and others	83 (54.6%)
Driver gene EGFR/ALK/c-met
Mutant type	32 (21.1%)
Wild type	120 (78.9%)
Metastasis sites
≤3	82 (53.9%)
>3	70 (46.1%)
History of tumor surgery
Yes	66 (43.4%)
No	86 (56.6%)
Number of previous treatment lines
3	89 (58.6%)
>3	63 (41.4%)